 GARDEN CITY, NY, Jan. 05, 2021 GLOBE NEWSWIRE -- ProPhase Labs, Inc. NASDAQ: PRPH, a diversified medical science and technology company, today announced that it has entered into a definitive securities purchase agreement with certain institutional and accredited investors to purchase, in a registered direct offering, 550,000 shares of ProPhase common stock, at a purchase price of 10.00 per share, together with warrants to purchase 275,000 shares of ProPhase common stock at a purchase price of 11.00 per share. Subject to customary closing conditions, the transaction is expected to close on Thursday, January 7, 2021. 